Systemic lupus erythematosus in Asturias, Spain: clinical and serologic features.
Asturias is an autonomous region in the north of Spain with historical and anthropologic peculiarities. In the current report, we examine the main clinical and immunologic features of 363 patients with systemic lupus erythematosus (SLE), virtually the entire population of SLE patients in Asturias. We constructed a database with the clinical and immunologic features of all patients fulfilling the American College of Rheumatology criteria, based on the review of hospital records corresponding to blood samples received for antinuclear antibodies testing since 1992. Arthritis was the most frequently observed main clinical feature and neuropathy was the rarest. Male patients had a disease more frequently characterized by serositis (p<0.05) and neurologic disorder (p<0.01) than females, while children presented malar rash (p<0.05), fever (p<0.05), and kidney involvement (p<0.01) more often than adults. Late-onset patients were characterized by lower frequencies of malar rash (p<0.01), neurologic disorder (p<0.05), alopecia (p<0.01), and lymphadenopathy (p<0.05) than young adults. Numerous direct and inverse significant associations were found among clinical and immunologic features. The most relevant significant associations were neurologic disorder with lupus anticoagulant (p<0.01); kidney involvement with serositis (p<0.01) and DNA antibodies (p<0.05); and thrombosis with DNA antibodies (p<0.05), cardiolipin antibodies (p<0.01), and lupus anticoagulant (p<0.01). A low mortality was found in our series, although kidney involvement (p<0.05) and cardiolipin antibodies (p<0.05) are factors associated with poor survival.
Gómez
Jesús
J
From Immunology Department (JG, LM, CG), and Internal Medicine Department (JBD), Hospital Universitario Central de Asturias; and Deparment of Functional Biology (AS, PL, CG), Immunology Area, University of Oviedo, Asturias, Spain.
Suárez
Ana
A
López
Patricia
P
Mozo
Lourdes
L
Díaz
José Bernardino
JB
Gutiérrez
Carmen
C
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D017668:Age of Onset; D000974:Antibodies, Antinuclear / Q000097:blood*; D002648:Child; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000175:diagnosis* / Q000453:epidemiology* / Q000503:physiopathology; D008206:Lymphatic Diseases / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012261:Ribonucleoproteins / Q000097:blood / Q000276:immunology; D016036:Seroepidemiologic Studies; D012700:Serositis / Q000503:physiopathology; D012737:Sex Factors; D013030:Spain / Q000453:epidemiology; D016019:Survival Analysis
D000974:Antibodies, Antinuclear; D012261:Ribonucleoproteins